Spero Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
SPRO$1.01-5.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
STOCKHOLDERS’ EQUITY
(In thousands, except unit and share amounts)
| Additional · Total | |||||
|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Stockholders' | |||||
| Shares | Par Value | Capital | Deficit | Equity | |
| Balances at December 31, 2023 | 52,999,680 | $53 | $497,913 | $(391,072) | $106,894 |
| Issuance of common stock upon the vesting of restricted stock units and performance stock units | 1,593,847 | 2 | — | — | 2 |
| Share-based compensation expense | — | — | 7,793 | — | 7,793 |
| Net loss | — | — | — | (68,566) | (68,566) |
| Balances at December 31, 2024 | 54,593,527 | $55 | $505,706 | $(459,638) | $46,123 |
| Issuance of common stock upon the vesting of restricted stock units | 1,821,130 | 1 | — | — | 1 |
| Share-based compensation expense | — | — | 4,325 | — | 4,325 |
| Net income | — | — | — | 8,572 | 8,572 |
| Balances at December 31, 2025 | 56,414,657 | $56 | $510,031 | $(451,066) | $59,021 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.